Aim To evaluate the perioperative and survival outcomes of hepatic resections for ovarian cancer derived liver metastases, as part of cytoreductive surgery.

Methodology A university tertiary hepatic center database was investigated retrospectively for patients with primary and recurrent ovarian cancer who underwent liver resection as part of cytoreductive surgery from January 1992 to December 2022.

Results Disease-specific (DSS) and overall survival (OS) was defined as the time elapsed between the hepatic resection and tumour-related and all-cause death, respectively. All survival models were adjusted for the year of tumour diagnosis.

A total of 45 patients (age: 58:76 ± 13,36 years, mean ± standard deviation), of whom 9 and 36 had primary and recurrent ovarian tumour, respectively, were included. 5 (55.56%) and 30 (83.33%) from the primary and recurrent groups had histologically confirmed hepatic metastasis (HepMet). Colon (77.14% vs. 30%; p = 0.0091) and greater omentum (77.14% vs. 40%; p = 0.0488) resection, and the prior use of chemotherapy (82.86% vs. 40%; p = 0.0133) was more common in the HepMet group.

Although the univariate effect of hepatic metastases over patient survival could not be justified neither for OS (p = 0.2835) nor for DSS (p = 0.6718), its significant effect over DSS was justifiable in a multivariate setting. If analysed together with age (p = 0.0018), peritoneal carcinosis index (p = 0.0204), body-mass index (p = 0.3078) and HIPEC during the surgery (p = 0.0252), it was a significant effector of patient survival (p = 0.0394).

• Download figure
• Open in new tab
• Download powerpoint

Abstract #1072 Figure 1

Conclusion Complete cytoreductive surgery with inclusion of hepatic resection for advanced and recurrent ovarian cancer is feasible and may confer survival benefit.

Disclosures No conflicts of interest